What we're reading, February 4, 2016: President Obama is proposing changes to the widely disliked Cadillac tax; Florida declares a health emergency in 4 counties over Zika virus; and drug makers are pouring money into efforts to improve medication adherence.
President Obama has shown willingness to alter the Cadillac tax, a controversial part of the Affordable Care Act that even Democrats have begun to speak out against. The New York Times reported that a senior White House advisor confirmed the president’s 2017 budget plan will include a proposal to tailoring the tax to reflect regional differences across the country. Parts of the country where healthcare is particularly expensive will have a higher threshold, according to the proposed change.
Panic over the Zika virus in the United States is increasing. Governor Rick Scott has declared a health emergency in 4 counties in Florida, all of which had confirmed cases, reported CBS Miami. In total, Florida has had 9 confirmed cases of the virus, all of which were contracted by people who traveled to Latin America and the Caribbean and none of whom were pregnant women. South Florida hospitals are also asking pregnant women when they are admitted if they have traveled to areas with the virus.
Patients may be upset at how costly drugs are getting, but the pharmaceutical industry probably isn’t too happy about the money it loses when patients don’t fill or refill their prescriptions. According to STAT, drug makers are pouring money into adherence programs to get patients to take their medications. They are investing in smart pills that send alerts if they haven’t been taken, gift cards to thank patients who do refill their prescription, and payment patients to talk about the benefits of taking medication as prescribed.
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Significant Disease Burden and Management Issues in Chronic Spontaneous Urticaria
April 15th 2025Patients with chronic spontaneous urticaria experienced a long delay in diagnosis, a substantial impact on their quality of life, and often received inadequate treatment, highlighting the need for better management and understanding of the condition.
Read More
Lifestyle Interventions, Statins, Among Keys to Mitigating CVD Risk in MASLD/MASH
April 15th 2025A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated steatohepatitis (MASH) and looks ahead to the future promise of glucagon-like peptide 1 (GLP-1) receptor agonists for liver conditions.
Read More